Liquidia Corp. (LQDA)
66.91
-1.26
(-1.85%)
USD |
NASDAQ |
Sep 01, 16:00
68.00
+1.09
(+1.63%)
After-Hours: 06:31
Liquidia Research and Development Expense (Annual) : 38.45M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 38.45M |
| December 31, 2024 | 46.54M |
| December 31, 2023 | 42.06M |
| December 31, 2022 | 17.68M |
| December 31, 2021 | 18.97M |
| Date | Value |
|---|---|
| December 31, 2020 | 30.72M |
| December 31, 2019 | 37.70M |
| December 31, 2018 | 28.70M |
| December 31, 2017 | 24.75M |
| December 31, 2016 | 23.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Indivior Pharmaceuticals, Inc. | 80.00M |
| Harmony Biosciences Holdings, Inc. | 189.59M |
| Johnson & Johnson | 14.83B |
| United Therapeutics Corp. | 550.00M |
| Amneal Pharmaceuticals, Inc. | 186.18M |